Products
First RECRUIT-TandAb® AFM13 entered clinical trials in 2010!
click the image to see it in full size
Lead Products
TandAbs® are widely applicable and show promising therapeutic benefits in a broad range of diseases. In September 2010, Affimed initiated phase I clinical trials for its lead drug AFM13 to treat Hodgkin Lymphoma. In this phase I study the dose is being gradually escalated in order to assess safety and tolerability in Hodgkin Lymphoma patients.
AFM11 and AFM12 are in preclinical development to treat Non-Hodgkin Lymphoma (NHL). AFM11 binds to the molecular targets on cancer (CD19) and cytotoxic T cells (CD3), while AFM12 binds to CD19 and to CD16A (the receptor on NK cells). AFM11 is in late preclinical development.
Product Pipeline
TandAbs® are widely applicable and show promising therapeutic benefits in a broad range of indications. The deep pipeline Affimed is building, as well as the rate at which we are advancing compounds through the clinic, show the broad range of our capabilities. Combined with this, Affimed has a strong IP position with wide patent protection.
|
Compound
-
(target)
|
Indication |
Discovery |
Preclinical |
Phase I |
Phase II |
|
AFM13
-
(CD30xCD16)
|
Hodgkin Lymphoma |
100% completed
|
100% completed
|
70 %
100%
|
|
|
AFM11
-
(CD19xCD3)
|
Non-Hodgkin Lymphoma |
100% completed
|
50 %
100%
|
100%
|
|
|
AFM12
-
(CD19xCD16)
|
Non-Hodgkin Lymphoma |
100% completed
|
50 %
100 %
|
-
|
-
|
Discovery Portfolio
We have been building a growing pipeline of preclinical therapeutic antibodies targeting a broad range of applications and indications. Our preclinical candidates AFM15, AFM19, AFM20 and AFM21 for the treatment of autoimmune diseases, asthma and solid tumors have recently completed preclinical proof-of-principle studies and are also available for partnering.
Our Discovery Portfolio
TandAb® Technology
TandAbs®, which were invented and developed by Affimed scientists, are tetravalent bispecific antibody formats that have two binding sites for each antigen. They bind to target molecules on the surface of, for example, tumor cells and can activate immune effector cells like cytotoxic T-cells or natural killer (NK) cells. TandAbs® possess the same avidity and affinity for each target as an IgG. Combined with their bispecificity, this format represents a unique and superior alternative to first generation antibody formats/scaffolds. In addition, TandAbs® have an excellent safety profile because they lack an Fc-portion. Production and downstream processing for TandAbs® have been established in eukaryotic cells and E.coli. The TandAb® molecules display excellent monomer stability, making TandAb® antibodies a potent alternative to therapeutic monoclonal antibodies.
TandAb® RECRUIT
Affimed´s original know-how of the activation process of cytotoxic immune cells, such as natural killer (NK) cells and cytotoxic T-cells, and the ability to isolate specific antibodies and generate novel antibody formats was crucial to the development of RECRUIT-TandAb®.
TandAb® RECRUIT
TandAb® BIBLOCK
The second pillar of our technology is the BiBLOCK-TandAb®. Signaling pathways often work synergistically to enhance activation or inhibition. The unique advantage of our BiBLOCK-TandAbs® is the simultaneous blocking of 2 targets by two binding sites for each target.
TandAb® BIBLOCK
